Vanaja Donkena Krishna, Grossmann Michael E, Cheville John C, Gazi Mozammel H, Gong Aiyu, Zhang Jin San, Ajtai Katalin, Burghardt Thomas P, Young Charles Y F
Department of Urology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Cancer Invest. 2009 Mar;27(3):264-72. doi: 10.1080/07357900802406319.
We investigated the molecular function of PDLIM4 in prostate cancer cells. PDLIM4 mRNA and protein-expression levels were reduced in LNCaP, LAPC4, DU145, CWR22, and PC3 prostate cancer cells. The re-expression of PDLIM4 in prostate cancer cells has significantly reduced the cell growth and clonogenicity with G1 phase of cell-cycle arrest. We have shown the direct interaction of PDLIM4 with F-actin. Restoration of PDLIM4 expression resulted in reduction of tumor growth in xenografts. These results suggest that PDLIM4 may function as a tumor suppressor, involved in the control of cell proliferation by associating with actin in prostate cancer cells.
我们研究了PDLIM4在前列腺癌细胞中的分子功能。在LNCaP、LAPC4、DU145、CWR22和PC3前列腺癌细胞中,PDLIM4 mRNA和蛋白表达水平降低。在前列腺癌细胞中重新表达PDLIM4可显著降低细胞生长和克隆形成能力,并使细胞周期停滞于G1期。我们已经证明PDLIM4与F-肌动蛋白直接相互作用。恢复PDLIM4表达可导致异种移植瘤生长减少。这些结果表明,PDLIM4可能作为一种肿瘤抑制因子,通过与前列腺癌细胞中的肌动蛋白结合参与细胞增殖的控制。